Medication info
Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide Tablets 2.5/20/12.5 mg

Olmesartan Medoxomil/Amlodipine Besylate/Hydrochlorothiazide Tablets 2.5/20/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tabletS-Amlodipine Besylate Dihydrate›3.69mg / 1 tablet
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
White and orange round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 202401354 · Approved 2024.05.31 · Insurance code 653405750

Summary

Main use
Treatment of essential hypertension not adequately controlled with the combination of S-amlodipine and olmesartan
Who takes it
Adults · Children
Adult dose
This medication should be taken once daily as 1 tablet with water, with or without food. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (s-amlodipine (amlodipine) and olmesartan medoxomil) as monotherapy or combination therapy. However, if blood pressure is not controlled with combination therapy of s-amlodipine (amlodipine) and olmesartan medoxomil as follows, switching directly to this medication may be considered. The maximum dose of this medication is 5/40/25mg of s-amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses (in the order of s-amlodipine/olmesartan medoxomil/hydrochlorothiazide) are as follows. - 2.5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of s-amlodipine/olmesartan medoxomil 2.5/20mg (amlodipine/olmesartan medoxomil 5/20mg). - 2.5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of s-amlodipine/olmesartan medoxomil 2.5/40mg (amlodipine/olmesartan medoxomil 5/40mg) or with this medication 2.5/20/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). - 2.5/40/25mg: For patients whose blood pressure is not adequately controlled with this medication 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of s-amlodipine/olmesartan medoxomil 5/40mg (amlodipine/olmesartan medoxomil 10/40mg) or with this medication 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/25mg: For patients whose blood pressure is not adequately controlled with s-amlodipine/olmesartan medoxomil/hydrochlorothiazide 2.5/40/25mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/25mg) or with this medication 5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 10/40/12.5mg). ※ Refer to the following dose-escalation schedule. The content of each component is listed in the order of s-amlodipine/olmesartan medoxomil/hydrochlorothiazide (amlodipine/olmesartan medoxomil/hydrochlorothiazide) 2.5/20/0mg (5/20/0mg) → 2.5/20/12.5mg (5/20/12.5mg) ↓ 2.5/40/0mg (5/40/0mg) → 2.5/40/12.5mg (5/40/12.5mg) → 2.5/40/25mg (5/40/25mg) ↓ ↓ 5/40/0mg (10/40/0mg) → 5/40/12.5mg (10/40/12.5mg) → 5/40/25mg (10/40/25mg) Patients with renal impairment The maximum dose of this medication for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 2.5/20/12.5 milligrams once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medication should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medication to patients with mild or moderate hepatic impairment. The maximum dose of this medication for patients with moderate hepatic impairment is 2.5/20/12.5 milligrams once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medication should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) In general, treatment should be initiated at a low dose, and the patient's renal or cardiac function and comorbidities should be taken into consideration when adjusting the dose. Blood pressure should be monitored closely and more frequently in older adults. In particular, experience with the use of this medication in adults aged 75 years and older is very limited; therefore, patients in this age group should be monitored very carefully when receiving this medication.
Child dose
Pediatric patients under 18 years of age: The safety and efficacy have not been established; therefore, use of this drug is not recommended.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not adequately controlled with the combination of S-amlodipine and olmesartan

  • Essential hypertension
View approved original text

This combination of Amlodipine and Olmesartan Medoxomil is used when blood pressure control is inadequate in patients with essential hypertension. These medications help effectively manage high blood pressure by dilating blood vessels and lowering blood pressure. The use of the combination contributes to stable blood pressure control, reducing the risk of cardiovascular complications. Consistent use and regular blood pressure monitoring are important, and better effects can be expected when used in conjunction with a healthy lifestyle. This combination is useful for the treatment of essential hypertension.

How to take

Adult dose

This medication should be taken once daily as 1 tablet with water, with or without food. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (s-amlodipine (amlodipine) and olmesartan medoxomil) as monotherapy or combination therapy. However, if blood pressure is not controlled with combination therapy of s-amlodipine (amlodipine) and olmesartan medoxomil as follows, switching directly to this medication may be considered. The maximum dose of this medication is 5/40/25mg of s-amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses (in the order of s-amlodipine/olmesartan medoxomil/hydrochlorothiazide) are as follows. - 2.5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of s-amlodipine/olmesartan medoxomil 2.5/20mg (amlodipine/olmesartan medoxomil 5/20mg). - 2.5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of s-amlodipine/olmesartan medoxomil 2.5/40mg (amlodipine/olmesartan medoxomil 5/40mg) or with this medication 2.5/20/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). - 2.5/40/25mg: For patients whose blood pressure is not adequately controlled with this medication 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of s-amlodipine/olmesartan medoxomil 5/40mg (amlodipine/olmesartan medoxomil 10/40mg) or with this medication 2.5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/12.5mg). - 5/40/25mg: For patients whose blood pressure is not adequately controlled with s-amlodipine/olmesartan medoxomil/hydrochlorothiazide 2.5/40/25mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/40/25mg) or with this medication 5/40/12.5mg (amlodipine/olmesartan medoxomil/hydrochlorothiazide 10/40/12.5mg). ※ Refer to the following dose-escalation schedule. The content of each component is listed in the order of s-amlodipine/olmesartan medoxomil/hydrochlorothiazide (amlodipine/olmesartan medoxomil/hydrochlorothiazide) 2.5/20/0mg (5/20/0mg) → 2.5/20/12.5mg (5/20/12.5mg) ↓ 2.5/40/0mg (5/40/0mg) → 2.5/40/12.5mg (5/40/12.5mg) → 2.5/40/25mg (5/40/25mg) ↓ ↓ 5/40/0mg (10/40/0mg) → 5/40/12.5mg (10/40/12.5mg) → 5/40/25mg (10/40/25mg) Patients with renal impairment The maximum dose of this medication for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 2.5/20/12.5 milligrams once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medication should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Caution should be exercised when administering this medication to patients with mild or moderate hepatic impairment. The maximum dose of this medication for patients with moderate hepatic impairment is 2.5/20/12.5 milligrams once daily (amlodipine/olmesartan medoxomil/hydrochlorothiazide 5/20/12.5mg). Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medication should not be administered to patients with severe hepatic impairment. Older adults (65 years and older) In general, treatment should be initiated at a low dose, and the patient's renal or cardiac function and comorbidities should be taken into consideration when adjusting the dose. Blood pressure should be monitored closely and more frequently in older adults. In particular, experience with the use of this medication in adults aged 75 years and older is very limited; therefore, patients in this age group should be monitored very carefully when receiving this medication.

Child dose

Pediatric patients under 18 years of age: The safety and efficacy have not been established; therefore, use of this drug is not recommended.

Precautions

This medication can cause serious harm or death to the fetus or newborn if taken during the second and third trimesters of pregnancy, therefore it should be stopped immediately if pregnancy is confirmed. Patients with a history of allergic reactions to this medication or similar drugs, pregnant or nursing women, patients with severe hypotension, and those with significantly impaired heart and kidney functions should not take this medication. Patients with reduced blood volume, kidney function issues, severely impaired liver function, and certain heart valve diseases should use this medication cautiously and monitor their condition closely before and after administration. Due to the blood pressure-lowering effects of this drug, dizziness and lightheadedness may occur, so caution is needed when driving or operating dangerous machinery. This medication may cause electrolyte imbalances in the body, so it is essential to regularly check levels of sodium, potassium, calcium, magnesium, and other electrolytes in the blood. Patients taking this medication may experience increased sensitivity of the skin to sunlight, so it is advisable to avoid sun exposure and to take appropriate protective measures if necessary. Using this medication in combination with certain drugs may enhance blood pressure-lowering effects or increase the risk of side effects, so it is crucial to consult a doctor or pharmacist if taking other medications. This medication is not recommended for children under 18 years of age as its safety and efficacy are not established. Elderly patients may have reduced kidney and liver function, so start with a lower dose and adjust carefully. Overdose can result in severe hypotension, palpitations, electrolyte imbalances, etc., and immediate medical treatment should be sought. Store this medication away from direct sunlight and moisture, in a tightly closed container, out of reach of children, and avoid transferring to another container.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, loss of appetite, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion state, depression, apathy, sensitivity to stimulation, anxiety, mood changes, sleep disorders, dizziness, orthostatic dizziness, syncope, taste disorders, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, decreased tearing, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina pectoris, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, change in bowel habits, bloating, dyspepsia, gastritis, stomach discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, pustular rash, exfoliative dermatitis, sweating, photosensitivity reaction, pruritus, purpura, Quincke's edema, rash, recurrence of skin lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, increased frequency of urination, acute renal failure, hematuria, voiding disorders, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, ennui, edema, pain, facial edema, increased serum creatinine, elevated blood urea, elevated serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, elevated liver enzymes, increased serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption, intestinal vascular edema, altered consciousness, drug hypersensitivity, upper abdominal pain, decreased libido, ascites, asthenia, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, abdominal distension, facial flushing, epistaxis, benign prostatic hyperplasia, prostate enlargement, prostatitis, dysphagia, papular rash, renal cell dysplasia, benign salivary gland neoplasm, acute hearing loss, cerebral infarction, lymphadenitis, choroidal effusion, acute respiratory distress syndrome (ARDS)

Not everyone experiences these, and they can vary from person to person.

Storage

This medication can be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

White and orange round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.